Fuchs, Anke and Gliwinski, Mateusz and Grageda, Nathali and Spiering, Rachel and Abbas, Abul K. and Appel, Silke and Bacchetta, Rosa and Battaglia, Manuela and Berglund, David and Blazar, Bruce and Bluestone, Jeffrey A. and Bornhaeuser, Martin and ten Brinke, Anja and Brusko, Todd M. and Cools, Nathalie and Cuturi, Maria Cristina and Geissler, Edward and Giannoukakis, Nick and Golab, Karolina and Hafler, David A. and van Ham, S. Marieke and Hester, Joanna and Hippen, Keli and Di Ianni, Mauro and Ilic, Natasa and Isaacs, John and Issa, Fadi and Iwaszkiewicz-Grzes, Dorota and Jaeckel, Elmar and Joosten, Irma and Klatzmann, David and Koenen, Hans and van Kooten, Cees and Korsgren, Olle and Kretschmer, Karsten and Levings, Megan and Marek-Trzonkowska, Natalia Maria and Martinez-Llordella, Marc and Miljkovic, Djordje and Mills, Kingston H. G. and Miranda, Joana P. and Piccirillo, Ciriaco A. and Putnam, Amy L. and Ritter, Thomas and Roncarolo, Maria Grazia and Sakaguchi, Shimon and Sanchez-Ramon, Silvia and Sawitzki, Birgit and Sofronic-Milosavljevic, Ljiljana and Sykes, Megan and Tang, Qizhi and Vives-Pi, Marta and Waldmann, Herman and Witkowski, Piotr and Wood, Kathryn J. and Gregori, Silvia and Hilkens, Catharien M. U. and Lombardi, Giovanna and Lord, Phillip and Martinez-Caceres, Eva M. and Trzonkowski, Piotr (2018) Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. FRONTIERS IN IMMUNOLOGY, 8: 1844. ISSN 1664-3224,
Full text not available from this repository. (Request a copy)Abstract
Cellular therapies with CD4+ T regulatory cells (Tregs) hold promise of efficacious treatment for the variety of autoimmune and allergic diseases as well as posttransplant complications. Nevertheless, current manufacturing of Tregs as a cellular medicinal product varies between different laboratories, which in turn hampers precise comparisons of the results between the studies performed. While the number of clinical trials testing Tregs is already substantial, it seems to be crucial to provide some standardized characteristics of Treg products in order to minimize the problem. We have previously developed reporting guidelines called minimum information about tolerogenic antigen-presenting cells, which allows the comparison between different preparations of tolerance-inducing antigen-presenting cells. Having this experience, here we describe another minimum information about Tregs (MITREG). It is important to note that MITREG does not dictate how investigators should generate or characterize Tregs, but it does require investigators to report their Treg data in a consistent and transparent manner. We hope this will, therefore, be a useful tool facilitating standardized reporting on the manufacturing of Tregs, either for research purposes or for clinical application. This way MITREG might also be an important step toward more standardized and reproducible testing of the Tregs preparations in clinical applications.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | CHIMERIC ANTIGEN RECEPTOR; VERSUS-HOST-DISEASE; ADOPTIVE TRANSFER; IN-VITRO; TRANSPLANTATION; BLOOD; EXPANSION; ALLOGRAFT; TOLERANCE; THERAPIES; minimum information model; T regulatory cells; immunotherapy; good manufacturing practice; cell therapy; immune tolerance |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Chirurgie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 23 Mar 2020 15:03 |
| Last Modified: | 23 Mar 2020 15:03 |
| URI: | https://pred.uni-regensburg.de/id/eprint/15196 |
Actions (login required)
 |
View Item |
